These studies suggest that pharmacologic abrogation of AR both in prostate cancer (darolutamide and enzalutamide) and in AR+ TNBC (enzalutamide) may be a viable treatment strategy for the radiosensitization of aggressive tumors, as AR inhibition may inhibit DNA repair. The gene discussed is AR; the disease is prostate carcinoma.